keyword
MENU ▼
Read by QxMD icon Read
search

Prescription drug pricing

keyword
https://www.readbyqxmd.com/read/28271587/strategies-for-reduction-in-the-duration-of-intravenous-drug-use-interest-of-drug-tracers-as-quality-indicators-to-improve-intravenous-to-oral-switch
#1
Jennifer Corny, Simon Perreau, Anne-Pauline Thivilliers, Céline Leplay, Delphine Chevalier, Hélène Beaussier, Yvonnick Bézie
RATIONALE, AIMS, AND OBJECTIVES: Intravenous (IV) to oral (PO) drug switch is a challenge for tertiary care institutions for several reasons: catheter-related infections, patient's pain and discomfort or higher costs, and overuse of IV drugs considered as an irrational use of medicines. The objective was to evaluate yearly acetaminophen and proton-pump inhibiters' (PPIs) IV/PO ratios from 2011 to 2015 and to determine their correlation with all drugs IV/PO ratios and their relevance as drug tracers...
March 7, 2017: Journal of Evaluation in Clinical Practice
https://www.readbyqxmd.com/read/28250671/generic-versus-branded-medicines-an-observational-study-among-patients-with-chronic-diseases-attending-a-public-hospital-outpatient-department
#2
Manisha Das, Supriyo Choudhury, Somnath Maity, Avijit Hazra, Tirthankar Pradhan, Aishee Pal, Ranendra Kumar Roy
BACKGROUND: The concept of generic prescription is widely accepted in various parts of the world. Nevertheless, it has failed to gain popularity in India due to factors such as nonavailability and distrust on the product quality. However, since 2012, the Government of West Bengal, India, has initiated exclusive generic drug outlets called "fair price medicine shop" (FPMS) inside the government hospital premises in a "public-private-partnership" model. This study was undertaken to evaluate the experience and attitude of patients who were consuming generic drugs purchased from these FPMS...
January 2017: Journal of Natural Science, Biology, and Medicine
https://www.readbyqxmd.com/read/28249992/effect-of-cost-sharing-on-adherence-to-evidence-based-medications-in-patients-with-acute-coronary-syndrome
#3
Beatriz González López-Valcárcel, Julián Librero, Aníbal García-Sempere, Luz María Peña, Sofía Bauer, Jaume Puig-Junoy, Juan Oliva, Salvador Peiró, Gabriel Sanfélix-Gimeno
OBJECTIVES: Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. METHODS: Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009-2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%...
March 1, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28246223/estimated-effects-of-adding-universal-public-coverage-of-an-essential-medicines-list-to-existing-public-drug-plans-in-canada
#4
Steven G Morgan, Winny Li, Brandon Yau, Nav Persaud
BACKGROUND: Canada's universal health care system does not include universal coverage of prescription drugs. We sought to estimate the effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. METHODS: We used administrative and market research data to estimate the 2015 shares of the volume and cost of prescriptions filled in the community setting that were for 117 drugs on a model list of essential medicines for Canada...
February 27, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28230452/prescription-drug-utilization-and-reimbursement-increased-following-state-medicaid-expansion-in-2014
#5
Nirosha Mahendraratnam, Stacie B Dusetzina, Joel F Farley
BACKGROUND: The Affordable Care Act (ACA) expanded health care and medication insurance coverage through Medicaid expansion in select states. Expansion has the potential to increase the availability of health services to patients, including prescription medications. However, limited studies have examined how expansion affected prescription drug utilization and reimbursement. OBJECTIVE: To compare prescription drug utilization (number of prescriptions filled) and reimbursement trends between states that did and did not expand Medicaid coverage in 2014, while accounting for known effects of expansion on Medicaid enrollment...
March 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28224469/the-medicaid-rebate-changes-in-oncology-drug-prices-after-the-affordable-care-act
#6
Ali Bonakdar Tehrani, Norman V Carroll
BACKGROUND: Prescription drug spending is a significant component of Medicaid total expenditures. The Affordable Care Act (ACA) includes a provision that increases the Medicaid rebate for both brand-name and generic drugs. This study examines the extent to which oncology drug prices changed after the increase in the Medicaid rebate in 2010. METHODS: A pre-post study design was used to evaluate the correlation between the Medicaid rebate increase and oncology drug prices after 2010 using 2006-2013 State Drug Utilization Data...
February 21, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28212657/pharmacists-views-and-reported-practices-in-relation-to-a-new-generic-drug-substitution-policy-in-lebanon-a-mixed-methods-study
#7
Fadi El-Jardali, Racha Fadlallah, Rami Z Morsi, Nour Hemadi, Mounir Al-Gibbawi, Magda Haj, Suzan Khalil, Youssef Saklawi, Diana Jamal, Elie A Akl
BACKGROUND: Governments in both developed and developing countries have adopted generic drug substitution policies to decrease pharmaceutical expenditures and improve access to medicine. In August 2015, the Ministry of Public Health (MOPH) in Lebanon introduced generic drug substitution and a unified medical prescription form as policy instruments to promote generic drug use. The objective of this exploratory study was to examine the attitudes of community pharmacists and the reported practices in relation to the implementation of the new generic drug substitution policy...
February 17, 2017: Implementation Science: IS
https://www.readbyqxmd.com/read/28210864/pharmacy-benefit-management-companies-do-they-create-value-in-the-us-healthcare-system
#8
Alan Lyles
Pharmacy benefit management companies (PBMs) perform functions in the US market-based healthcare system that may be performed by public agencies or quasi-public institutions in other nations. By aggregating lives covered under their many individual contracts with payers, PBMs have formidable negotiating power. They influence pharmaceutical insurance coverage, design the terms of coverage in a plan's drug benefit, and create competition among providers for inclusion in a plan's network. PBMs have, through intermediation, the potential to secure lower drug prices and to improve rational prescribing...
February 16, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28202501/national-health-expenditure-projections-2016-25-price-increases-aging-push-sector-to-20%C3%A2-percent-of-economy
#9
Sean P Keehan, Devin A Stone, John A Poisal, Gigi A Cuckler, Andrea M Sisko, Sheila D Smith, Andrew J Madison, Christian J Wolfe, Joseph M Lizonitz
Under current law, national health expenditures are projected to grow at an average annual rate of 5.6 percent for 2016-25 and represent 19.9 percent of gross domestic product by 2025. For 2016, national health expenditure growth is anticipated to have slowed 1.1 percentage points to 4.8 percent, as a result of slower Medicaid and prescription drug spending growth. For the rest of the projection period, faster projected growth in medical prices is partly offset by slower projected growth in the use and intensity of medical goods and services, relative to that observed in 2014-16 associated with the Affordable Care Act coverage expansions...
February 15, 2017: Health Affairs
https://www.readbyqxmd.com/read/28199007/accuracy-of-claims-based-algorithms-for-epilepsy-research-revealing-the-unseen-performance-of-claims-based-studies
#10
Lidia M V R Moura, Maggie Price, Andrew J Cole, Daniel B Hoch, John Hsu
OBJECTIVE: To evaluate published algorithms for the identification of epilepsy cases in medical claims data using a unique linked dataset with both clinical and claims data. METHODS: Using data from a large, regional health delivery system, we identified all patients contributing biologic samples to the health system's Biobank (n = 36K). We identified all subjects with at least one diagnosis potentially consistent with epilepsy, for example, epilepsy, convulsions, syncope, or collapse, between 2014 and 2015, or who were seen at the epilepsy clinic (n = 1,217), plus a random sample of subjects with neither claims nor clinic visits (n = 435); we then performed a medical chart review in a random subsample of 1,377 to assess the epilepsy diagnosis status...
February 15, 2017: Epilepsia
https://www.readbyqxmd.com/read/28186712/a-practical-methodology-for-disaggregating-the-drivers-of-drug-costs-using-administrative-data
#11
Elena R Lungu, Orlando J Manti, Mitchell A H Levine, Douglas A Clark, Tanya M Potashnik, Carol I McKinley
BACKGROUND: Prescription drug expenditures represent a significant component of health care costs in Canada, with estimates of $28.8 billion spent in 2014. Identifying the major cost drivers and the effect they have on prescription drug expenditures allows policy makers and researchers to interpret current cost pressures and anticipate future expenditure levels. OBJECTIVES: To identify the major drivers of prescription drug costs and to develop a methodology to disaggregate the impact of each of the individual drivers...
September 1, 2017: Journal of Population Therapeutics and Clinical Pharmacology
https://www.readbyqxmd.com/read/28154326/marketing-approval-of-ethical-kampo-medicines
#12
Takashi Hakamatsuka
 Kampo medicine is an original traditional medicine in Japan. Currently, 148 ethical Kampo formulations (Kampo prescription drugs) are registered in the National Health Insurance Price List. Kampo medicines can be prescribed under the national insurance system, which shows that they are part of conventional medicine in Japan. Japan has a unified drug approval system that does not distinguish between Western and Kampo medicines, and both are subject to the same regulations. The application for the market approval of ethical Kampo medicines is based on the general notification for drugs, i...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28144847/-practices-of-caregivers-and-national-recommendations-for-treatment-of-malaria-in-benin-in-2009
#13
S Robin, C Bruneton, E Guévart
New treatments against malaria (artemisinin-based combination therapies, ACT) resulted in profound changes in the therapeutic behaviours in Africa. This study aims to evaluate the practices adaptation to the new strategies in Benin in 2009. In three southern areas of the country, 14 private pharmacies, 10 public health centers and 10 private health centers were audited. Between July and October 2009, 36 providers and 93 prescribers were interviewed, 127 dispensations for self-medication were observed, 210 prescriptions were analyzed according to the WHO recommendations, 251 patients with complaints of malaria and 50 healthy women were interviewed and 34 physical inventories were conducted in pharmacies...
January 31, 2017: Bulletin de la Société de Pathologie Exotique
https://www.readbyqxmd.com/read/28141931/the-challenge-of-paying-for-cost-effective-cures
#14
Patricia J Zettler, Erin C Fuse Brown
In this article, we consider the problem of financing highly effective and cost-effective prescription drugs within a value-based pricing system. Precisely because these drugs are highly effective, their value-based prices may be quite expensive; and moreover, the value-based price of a cure ought to be set high enough to create incentives for innovation, otherwise these beneficial therapies may be underdeveloped. However, in our fragmented health insurance system, where patients move frequently between payers, these payers generally lack the incentives to pay value-based prices for cures because they cannot ensure that they will reap the long-term economic benefits...
January 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28109551/-economic-impact-of-optimising-antiretroviral-treatment-in-human-immunodeficiency-virus-infected-adults-with-suppressed-viral-load-in-spain-by-implementing-the-grade-a-1-evidence-recommendations-of-the-2015-gesida-national-aids-plan
#15
Esteban Ribera, José Manuel Martínez-Sesmero, Javier Sánchez-Rubio, Rafael Rubio, Juan Pasquau, José Luis Poveda, Alejandro Pérez-Mitru, Celia Roldán, Beatriz Hernández-Novoa
INTRODUCTION: The objective of this study is to estimate the economic impact associated with the optimisation of triple antiretroviral treatment (ART) in patients with undetectable viral load according to the recommendations from the GeSIDA/PNS (2015) Consensus and their applicability in the Spanish clinical practice. METHODS: A pharmacoeconomic model was developed based on data from a National Hospital Prescription Survey on ART (2014) and the A-I evidence recommendations for the optimisation of ART from the GeSIDA/PNS (2015) consensus...
January 18, 2017: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/28077465/cost-effectiveness-of-the-polypill-versus-risk-assessment-for-prevention-of-cardiovascular-disease
#16
Bart S Ferket, M G Myriam Hunink, Mohammed Khanji, Isha Agarwal, Kirsten E Fleischmann, Steffen E Petersen
OBJECTIVE: There is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower cardiovascular risk. We assessed the cost-effectiveness of a population approach with a polypill including a statin (simvastatin 20 mg) and three antihypertensive agents (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) and periodic risk assessment with different risk thresholds. METHODS: We developed a microsimulation model for lifetime predictions of CVD events, diabetes, and death in 259 146 asymptomatic UK Biobank participants aged 40-69 years...
April 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28063909/periprocedural-outcomes-comparing-fibroid-embolization-and-focused%C3%A2-ultrasound-a-randomized-controlled-trial-and-comprehensive-cohort-analysis
#17
Emily P Barnard, Ahmed M AbdElmagied, Lisa E Vaughan, Amy L Weaver, Shannon K Laughlin-Tommaso, Gina K Hesley, David A Woodrum, Vanessa L Jacoby, Maureen P Kohi, Thomas M Price, Angel Nieves, Michael J Miller, Bijan J Borah, Krzysztof R Gorny, Phyllis C Leppert, Lisa G Peterson, Elizabeth A Stewart
BACKGROUND: Uterine fibroids are a common problem for reproductive-aged women, yet little comparative effectiveness research is available to guide treatment choice. Uterine artery embolization and magnetic resonance imaging-guided focused ultrasound surgery are minimally invasive therapies approved by the US Food and Drug Administration for treating symptomatic uterine fibroids. The Fibroid Interventions: Reducing Symptoms Today and Tomorrow study is the first randomized controlled trial to compare these 2 fibroid treatments...
January 5, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28005548/cost-sharing-rates-increase-during-deep-recession-preliminary-data-from-greece
#18
Athanasios Gouvalas, Michael Igoumenidis, Mamas Theodorou, Kostas Athanasakis
BACKGROUND: Measures taken over the past four years in Greece to reduce pharmaceutical expenditure have led to significant price reductions for medicines, but have also changed patient cost-sharing rates for prescription drugs. This study attempts to capture the resulting increase in patients' out-of-pocket (OOP) expenses for prescription drugs during the 2011-2014 period. METHODS: The authors conducted a retrospective review of financial data derived from 39 883 prescriptions, dispensed at three randomly chosen pharmacies located in Lamia, central Greece...
May 28, 2016: International Journal of Health Policy and Management
https://www.readbyqxmd.com/read/27995706/prescription-drug-pricing-is-not-just-an-election-issue
#19
Gail R Wilensky
No abstract text is available yet for this article.
December 2016: Milbank Quarterly
https://www.readbyqxmd.com/read/27987628/arbitration-board-setting-reimbursement-amounts-for-pharmaceutical-innovations-in-germany-when-price-negations-between-payers-and-manufacturers-fail-an-empirical-analysis-of-5-years-experience
#20
Saskia Ludwig, Charalabos-Markos Dintsios
BACKGROUND: In Germany, an arbitration board is setting reimbursement amounts for drug innovations when price negations between payers and manufacturers fail. OBJECTIVE: To empirically analyze all arbitrations since the reform of Germany's Act to Reorganize the Pharmaceuticals' Market in the Statutory Health Insurance System came into effect. METHODS: All available relevant documents up to January 2016 were screened and the identified contentious issues between the negotiation parties extracted...
December 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
109178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"